Edition:
United Kingdom

PDL BioPharma Inc (PDLI.OQ)

PDLI.OQ on NASDAQ Stock Exchange Global Select Market

3.03USD
15 Dec 2017
Change (% chg)

$0.16 (+5.57%)
Prev Close
$2.87
Open
$2.86
Day's High
$3.06
Day's Low
$2.86
Volume
2,940,887
Avg. Vol
467,131
52-wk High
$3.55
52-wk Low
$1.93

Latest Key Developments (Source: Significant Developments)

NODEN PHARMA ANNOUNCES U.S. FDA APPROVAL OF TEKTURNA ORAL PELLETS
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Noden Pharma DAC::NODEN PHARMA ANNOUNCES FDA APPROVAL OF TEKTURNA®(ALISKIREN) ORAL PELLETS FOR THE TREATMENT OF HYPERTENSION IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER.NODEN PHARMA DAC SAYS PLANS TO MAKE TEKTURNA ORAL PELLETS AVAILABLE IN 2018​.‍NODEN PHARMA DAC SAYS NEW FORMULATION AND PEDIATRIC INDICATION WERE APPROVED THROUGH FDA PRIORITY REVIEW PROCESS​.  Full Article

PDL Biopharma urges Neos Therapeutics to provide update on sale process
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - PDL Biopharma :PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process.Reiterated that its proposal to acquire Neos Therapeutics Inc for $10.25 per share in cash will expire today at market close​.Decided it will not extend deadline for, or otherwise alter, its proposal​.  Full Article

PDL Biopharma Inc reports Q3 revenue $62.7 million
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - PDL Biopharma Inc :PDL Biopharma Inc announces third quarter 2017 financial results.Q3 revenue $62.7 million.PDL Biopharma Inc - ‍qtrly GAAP diluted EPS of $0.14​.  Full Article

PDL Biopharma issues response to Neos Therapeutics rejection of PDL acquisition proposal
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Pdl Biopharma Inc :PDL Biopharma issues statement in response to Neos Therapeutics rejection of PDL acquisition proposal.PDL Biopharma Inc - ‍PDL's proposal to Neos remains outstanding through November 8, 2017 & co will evaluate "all of its options" in interim​.  Full Article

PDL Biopharma announces settlement agreement with Valeant
Monday, 30 Oct 2017 

Oct 30 (Reuters) - PDL Biopharma Inc :PDL Biopharma announces settlement agreement with Valeant.PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment will be transferred to co pursuant to terms of Depomed royalty agreement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment to co will not recognized as revenue by Depomed​.PDL - ‍depomed, co to release Valeant from claims against it arising from royalty audit, Valeant's obligation to pay royalties during audit period​.PDL Biopharma Inc- ‍valeant will release Depomed, co from all claims against them as a result of audit and/or litigation​.PDL - ‍entered into settlement with Valeant that resolves matters relating to "alleged underpayment of royalties by Valeant"​.  Full Article

Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Neos Therapeutics Inc ::Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​.Says Neos board will respond to PDL proposal received on Oct 26 in due course​.  Full Article

PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Pdl Biopharma Inc :PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash.PDL Biopharma Inc - ‍PDL proposal is not subject to any financing conditions​.PDL Biopharma Inc - ‍PDL proposal will remain outstanding for a period of fourteen days​.PDL BioPharma Inc - ‍on June 23, 2017, PDL formally proposed to acquire Neos for $10.25 per share, a proposal Neos Board promptly rejected​.PDL BioPharma Inc - ‍reconfirming proposal to purchase Neos Therapeutics for a cash purchase price of $10.25 per share​.PDL BioPharma Inc - ‍following Neos' dilutive financing at $6.25 per share, PDL maintained its $10.25 proposal to Board​.  Full Article

PDL Biopharma reports Q2 adjusted earnings per share $0.09
Thursday, 4 Aug 2016 

PDL Biopharma Inc : Q2 revenue $21 million . PDL Biopharma announces second quarter 2016 financial results . On august 3, 2016, pdl board of directors decided to eliminate quarterly cash dividend payment . Q2 non-gaap earnings per share $0.09 .Q2 gaap earnings per share $0.03.  Full Article

PDL Biopharma dismisses quarterly cash dividend
Thursday, 4 Aug 2016 

PDL Biopharma Inc :Board of directors has decided to eliminate its quarterly cash dividend.  Full Article

PDL Biopharma files for mixed shelf of up to $250 mln
Friday, 10 Jun 2016 

PDL Biopharma Inc :Files for mixed shelf of up to $250 million - SEC filing.  Full Article

BRIEF-NODEN PHARMA ANNOUNCES U.S. FDA APPROVAL OF TEKTURNA ORAL PELLETS

* NODEN PHARMA ANNOUNCES FDA APPROVAL OF TEKTURNA®(ALISKIREN) ORAL PELLETS FOR THE TREATMENT OF HYPERTENSION IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER